UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 163

Sortiert nach

Referral of patients with fever of unknown origin to an expertise center has high diagnostic and therapeutic value

QJM : An International Journal of Medicine, 2017-12, Vol.110 (12), p.793-801

2017

Volltextzugriff (PDF)

Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases

Pharmacology & therapeutics (Oxford), 2022-07, Vol.235, p.108165-108165, Article 108165

2022

Volltextzugriff (PDF)

Design of peptide-based vaccines for cancer

Current medicinal chemistry, 2006-06, Vol.13 (14), p.1591

2006

Volltextzugriff (PDF)

Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses

Vaccine, 2000-07, Vol.18 (27), p.3174-3184

2000

Volltextzugriff (PDF)

Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

Vaccine, 1996-06, Vol.14 (9), p.930-938

1996

Volltextzugriff (PDF)

Cripto: A novel target for antibody-based cancer immunotherapy

Cancer research (Chicago, Ill.), 2004-06, Vol.64 (11), p.4018-4023

2004

Volltextzugriff (PDF)

Crystal Structure of a Non-canonical Low-affinity Peptide Complexed with MHC Class I: A New Approach For Vaccine Design

Journal of molecular biology, 2002-05, Vol.318 (5), p.1293-1305

2002

Volltextzugriff (PDF)

Developing C-reactive protein modulators as new treatments for inflammation

Acta crystallographica. Section A, Foundations and advances, 2023-08, Vol.79 (a2), p.C1038-C1038

2023

Volltextzugriff (PDF)

Aldehyde‐mannan antigen complexes target the MHC class I antigen‐presentation pathway

European journal of immunology, 2000-06, Vol.30 (6), p.1714-1723

2000

Volltextzugriff (PDF)

Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses

Vaccine, 2006-04, Vol.24 (16), p.3191-3202

2006

Volltextzugriff (PDF)

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1

Vaccine, 2000-04, Vol.18 (19), p.2059-2071

2000

Volltextzugriff (PDF)

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses

Proceedings of the National Academy of Sciences - PNAS, 1995-10, Vol.92 (22), p.10128-10132

1995

Volltextzugriff (PDF)

A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway

Vaccine, 2001-01, Vol.19 (11), p.1397-1405

2001

Volltextzugriff (PDF)

Generation of cellular immune responses to antigenic tumor peptides

Cellular and molecular life sciences : CMLS, 2000-02, Vol.57 (2), p.290-310

2000

Volltextzugriff (PDF)

Parameters for using mannan-MUC1 fusion protein to induce cellular immunity

Cancer Immunology, Immunotherapy, 1998, Vol.45 (6), p.321-326

1998

Volltextzugriff (PDF)

Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors

The Journal of immunology (1950), 2004-09, Vol.173 (5), p.3148-3154

2004

Volltextzugriff (PDF)

Preclinical Characterization and In Vivo Imaging Studies of an Engineered Recombinant Technetium-99m-Labeled Metallothionein-Containing Anti-Carcinoembryonic Antigen Single-Chain Antibody

The Journal of nuclear medicine (1978), 1998-01, Vol.39 (1), p.47-56

1998

Volltextzugriff (PDF)

Antibody Conjugates for the Treatment of Cancer

Immunological reviews, 1992-10, Vol.129 (1), p.57-80

1992

Volltextzugriff (PDF)

Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy

Cancer Immunology, Immunotherapy, 1997-08, Vol.44 (6), p.323-328

1997

Volltextzugriff (PDF)

Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen

Vaccine, 1997-10, Vol.15 (14), p.1586-1593

1997

Volltextzugriff (PDF)

Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier

Biomaterials, 2009-03, Vol.30 (7), p.1389-1400

2009

Volltextzugriff (PDF)

Receptor-Mediated Delivery of Antigens to Dendritic Cells: Anticancer Applications

Molecular pharmaceutics, 2007-01, Vol.4 (1), p.58-72

2007

Volltextzugriff (PDF)

Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan–human MUC1 conjugates

Vaccine, 1999-06, Vol.17 (20), p.2740-2752

1999

Volltextzugriff (PDF)

Monoclonal antibody-directed cytotoxic therapy : Potential in malignant diseases of aging

Drugs & aging, 1999-07, Vol.15 (1), p.1-13

1999

Volltextzugriff (PDF)

CTL in mice immunized with human mucin 1 are MHC-restricted

The Journal of immunology (1950), 1995-12, Vol.155 (11), p.5089

1995

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(103)
Life Sciences & Biomedicine
(99)
Animals
(95)
Mice
(82)
Humans
(80)
Biological And Medical Sciences
(62)
Immunology
(52)
Medical Sciences
(50)
Pharmacology. Drug Treatments
(42)
Antineoplastic Agents
(36)
Antibodies, Monoclonal - Therapeutic Use
(34)
Immunotherapy
(33)
Mice, Inbred Balb C
(29)
Female
(23)
Oncology
(23)
Mucin-1 - Immunology
(20)
Amino Acid Sequence
(19)
Mice, Inbred C57bl
(19)
Medicine, Research & Experimental
(16)
Mice, Inbred Cba
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Referral of patients with fever of unknown origin to an expertise center has high diagnostic and therapeutic value

Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases

Design of peptide-based vaccines for cancer

Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses

Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

Cripto: A novel target for antibody-based cancer immunotherapy

Crystal Structure of a Non-canonical Low-affinity Peptide Complexed with MHC Class I: A New Approach For Vaccine Design

Developing C-reactive protein modulators as new treatments for inflammation

Aldehyde‐mannan antigen complexes target the MHC class I antigen‐presentation pathway

Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses

A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway

Generation of cellular immune responses to antigenic tumor peptides

Parameters for using mannan-MUC1 fusion protein to induce cellular immunity

Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors

Preclinical Characterization and In Vivo Imaging Studies of an Engineered Recombinant Technetium-99m-Labeled Metallothionein-Containing Anti-Carcinoembryonic Antigen Single-Chain Antibody

Antibody Conjugates for the Treatment of Cancer

Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy

Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen

Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier

Receptor-Mediated Delivery of Antigens to Dendritic Cells: Anticancer Applications

Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan–human MUC1 conjugates

Monoclonal antibody-directed cytotoxic therapy : Potential in malignant diseases of aging

CTL in mice immunized with human mucin 1 are MHC-restricted

Suchergebnisse filtern